EDGAR Filing Documents for 0001104659-17-047822

Form S-3 - Registration statement under Securities Act of 1933:

SEC Accession No. 0001104659-17-047822

Filing Date

2017-07-28

Accepted

2017-07-28 17:17:26

Documents

Document Format Files

Seq	Description	Document	Type	Size
1	S-3	a17-18483_1s3.htm	S-3	578245
2	EX-4.2	a17-18483_1ex4d2.htm	EX-4.2	478523
3	EX-4.3	a17-18483_1ex4d3.htm	EX-4.3	494053
4	EX-4.4	a17-18483_1ex4d4.htm	EX-4.4	60925
5	EX-4.5	a17-18483_1ex4d5.htm	EX-4.5	60769
6	EX-5.1	a17-18483_1ex5d1.htm	EX-5.1	45353
7	EX-12.1	a17-18483_1ex12d1.htm	EX-12.1	60475
8	EX-23.1	a17-18483_1ex23d1.htm	EX-23.1	4256
9	GRAPHIC	g184831bei001.jpg	GRAPHIC	2619
	Complete submission text file	0001104659-17-047822.txt		1787419

Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406

Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640

Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)